In a key decision, the Centers for Medicare and Medicaid Services (CMS) said today that Medicare will not pay for the controversial Alzheimer’s drug Adulhelm until it sees positive results from a government-approved trial.
Subscribe to:
Post Comments (Atom)
< + > Device-Centric Mobile Security is Creating Big Risks in Healthcare BYOD Environments
The following is a guest article by Matt Stern, CISO at Hypori Bring Your Own Device deployments are common in healthcare today. Physicians...
No comments:
Post a Comment